Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 3/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 4/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517369 | 1.00 | MME (0.44) | MMEACECPA1ACE2ECE1 | |
| SCHEMBL9852025 | 1.00 | MME (0.44) | MMEACECPA1ACE2ECE1 | |
| SCHEMBL29697058 | 1.00 | MME (0.44) | MMEACECPA1ACE2ECE1 | |
| Hydrochloric Acid SCHEMBL23404070 | 0.98 | MME (0.43) | MMEACECPA1ACE2ECE1 | |
| Hydrochloric Acid SCHEMBL23404085 | 0.98 | MME (0.43) | MMEACECPA1ACE2ECE1 | |
| SCHEMBL30629769 | 0.96 | MME (0.42) | MMEACECPA1ACE2ECE1 | |
| SCHEMBL31169711 | 0.92 | BACE1 (0.51) | MMEACECPA1ACE2ECE1 | |
| SCHEMBL30068583 | 0.89 | BACE1 (0.44) | MMEACECPA1ACE2ECE1 | |
| SCHEMBL29696975 | 0.89 | BACE1 (0.44) | MMEACECPA1ACE2ECE1 | |
| SCHEMBL31447508 | 0.86 | DPP4 (0.42) | ECE1CTSDBACE1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4713025-A2 | DELIVERY OF DUAL PAYLOAD OF MMAF OR MMAE AND TLR7 AGONISTS | The Research Foundation for The State University of New York (US) | 2026-03-25 | — | — | EP | claimed |
| US-20250375530-A1 | ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LTD (GB) | 2025-12-11 | — | — | US | claimed |
| US-20250367315-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | SYNAFFIX BV (NL) | 2025-12-04 | — | — | US | claimed |
| EP-4637831-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | Synaffix B.V. (NL) | 2025-10-29 | — | — | EP | claimed |
| EP-4638722-A2 | ALPP-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | Almac Discovery Limited (GB) | 2025-10-29 | — | — | EP | claimed |
| US-20250269051-A1 | ROR1-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2025-08-28 | — | — | US | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| EP-4543489-A1 | ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES | Almac Discovery Limited (GB) | 2025-04-30 | — | — | EP | claimed |
| CN-118930362-A | Slow-release small-molecule peptide carbon-based fertilizer and composite carbon-based fertilizer with same | 北京锦绣新技术发展有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| WO-2022192134-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | IMMUNOGEN, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| WO-2022187809-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-09 | — | — | WO | claimed |
| WO-2022129622-A1 | ROR1-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2022-06-23 | — | — | WO | claimed |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-04-14 | — | — | US | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| CN-114032271-A | Oyster polypeptide and polypeptide powder with uric acid reducing effect as well as preparation method and application of oyster polypeptide and polypeptide powder | 浙江工业大学 | 2022-02-11 | — | — | CN | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | MME 1501/4885ACE 1733/4885CPA1 267/4885 |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VIP, AREG, MIF | MME 1501/4885ACE 1733/4885CPA1 267/4885 |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | MME 4355/4885ACE 4608/4885CPA1 3998/4885 |
| US-20250375530-A1 | ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES | EGFR, ROR1, ERBB2 | MME 1736/4885ACE 3913/4885CPA1 2423/4885 |
| US-20250269051-A1 | ROR1-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | RORB, RORA, RORC | MME 2449/4885ACE 3300/4885CPA1 1409/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | MME 961/4885ACE 2255/4885CPA1 238/4885 |
| US-20250367315-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | CD22, PBDC1, PA2G4 | MME 2428/4885ACE 3923/4885CPA1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.